Investigational drug · Phase 2
AK138D1
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Small Cell Lung Cancer, Breast Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "AK138D1"
First trial start
2026
Jun 6, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AK138D1", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Cancer
- Breast Cancer
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "AK138D1" as an intervention, largest first.
- A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast CancerPivotal-lookingNot yet recruiting
AkesoIndustry
NCT07560124 · 286 participants (planned) · Start Jun 6, 2026 · Primary completion Jun 6, 2028
Drug: AK138D1; Ivonescimab and 1 more · For: Breast Cancer
Sites: Beijing, China; Harbin, China; Chengdu, China
- A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung CancerPivotal-lookingRecruiting
AkesoIndustry
NCT07623356 · 265 participants (planned) · Start Jul 7, 2026 · Primary completion Jun 18, 2028
Drug: AK138D1; Ivonescimab and 1 more · For: Non-Small Cell Lung Cancer
Sites: Shanghai, China
AkesoIndustry
NCT07281326 · 200 participants (planned) · Start Oct 22, 2025 · Primary completion Oct 22, 2026
Drug: AK138D1 · For: Solid Cancer
Sites: Harbin, China
AkesoIndustry
NCT06730386 · 100 participants (planned) · Start Feb 24, 2025 · Primary completion Feb 26, 2028
Drug: AK138D1 · For: Solid Cancer
Sites: Blacktown, Australia; North Ryde, Australia; South Brisbane, Australia · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Non-Small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.